MarketCap
VistaGen Therapeutics VTGN
$ 0.24
0.25%
Facebook
X
Telegram
VistaGen Therapeutics Operating Income | VTGN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income VistaGen Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -72.1 M | -56 M | -33 M | -59.3 M | -9.77 M | -10.5 M | -20.8 M | -24.6 M | -14.2 M | -10.2 M | -17.9 M | -6.78 M | -5.03 M | -6.79 M | -9.04 M | -6.56 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.03 M | -72.1 M | -22.7 M |
Quarterly Operating Income VistaGen Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.5 M | -20.1 M | -15.8 M | -19.5 M | -20.1 M | -15.8 M | -12.1 M | -15.1 M | -14.2 M | -12.1 M | -7 M | -7.88 M | -6.78 M | -7 M | - | -9.77 M | -17.5 M | -19.8 M | -16.7 M | -10.5 M | -31.1 M | -20.5 M | -6.22 M | -5.3 M | -5.3 M | -3.29 M | -3.12 M | -5.96 M | -5.96 M | -5.35 M | -6.22 M | -7.19 M | -7.19 M | -7.43 M | -4.08 M | -2.87 M | -4.99 M | -2.26 M | -2.26 M | -2.64 M | -2.64 M | -3.1 M | -1.96 M | -2.14 M | -2.14 M | -5.39 M | -1.82 M | -1.12 M | -1.12 M | -1.11 M | -1.27 M | -1.45 M | -1.45 M | -1.22 M | -1.3 M | -1.92 M | -1.92 M | -1.68 M | -1.72 M | -2.85 M | -2.85 M | -1.81 M | -1.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.11 M | -31.1 M | -7.29 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M |  Britain |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Revolution Medicines
RVMD
|
-1.18 B | $ 207.32 | 0.24 % | $ 39.4 B |  USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-192 M | $ 101.8 | 0.08 % | $ 6.62 B | USA |
|
Rezolute
RZLT
|
-79.9 M | $ 4.4 | 0.88 % | $ 334 M | USA |
 |
Sana Biotechnology
SANA
|
-250 M | $ 3.45 | 0.77 % | $ 874 M | USA |
 |
Seer
SEER
|
-78 M | $ 1.95 | 0.26 % | $ 108 M | USA |
 |
Precigen
PGEN
|
-111 M | $ 6.87 | 0.14 % | $ 2.15 B | USA |
 |
SIGA Technologies
SIGA
|
23.7 M | $ 3.2 | 1.86 % | $ 229 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-273 M | $ 19.94 | 0.05 % | $ 1.73 B | USA |
 |
Soligenix
SNGX
|
-11.8 M | $ 0.38 | 1.18 % | $ 1.97 M | USA |
 |
Spruce Biosciences
SPRB
|
-36.5 M | $ 59.09 | 2.0 % | $ 45.3 M | USA |
 |
Sarepta Therapeutics
SRPT
|
-700 M | $ 20.94 | 0.04 % | $ 2.1 B | USA |
 |
Stoke Therapeutics
STOK
|
-20.6 M | $ 30.05 | 0.81 % | $ 1.78 B | USA |
 |
Sutro Biopharma
STRO
|
-158 M | $ 19.1 | 0.34 % | $ 162 M | USA |
 |
Shattuck Labs
STTK
|
-51.5 M | $ 6.5 | 0.29 % | $ 452 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
-62.3 M | $ 42.43 | 0.23 % | $ 2.4 B | USA |
 |
Savara
SVRA
|
-124 M | $ 5.53 | 2.98 % | $ 1.23 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-7.12 M | $ 2.24 | 0.45 % | $ 1.52 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
343 B | $ 18.32 | 1.49 % | $ 28.9 B |  Japan |
 |
Bio-Techne Corporation
TECH
|
252 M | $ 72.31 | 0.01 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
-56.4 M | $ 1.98 | 2.06 % | $ 77.7 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
2.16 B | $ 36.76 | 1.21 % | $ 42.1 B | Israel |
 |
TG Therapeutics
TGTX
|
123 M | $ 55.74 | 0.58 % | $ 8.04 B | USA |
 |
Trevi Therapeutics
TRVI
|
-49.3 M | $ 16.82 | 1.17 % | $ 2.27 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-110 M | $ 5.48 | 0.54 % | $ 1.75 B | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-7.54 M | $ 69.37 | 0.35 % | $ 193 M | Israel |
 |
UroGen Pharma Ltd.
URGN
|
-125 M | $ 43.82 | 0.02 % | $ 2.11 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
1.49 B | $ 497.97 | 2.12 % | $ 22.1 B | USA |
 |
Spero Therapeutics
SPRO
|
6.31 M | $ 1.19 | 0.41 % | $ 66.7 M | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
-385 M | $ 57.42 | 3.78 % | $ 6.59 B | USA |
 |
Jounce Therapeutics
JNCE
|
-52.2 M | - | - | $ 98.4 M | USA |
 |
NextCure
NXTC
|
-57.6 M | $ 8.42 | 7.67 % | $ 23.9 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-12.2 M | $ 5.26 | 0.75 % | $ 56 M | USA |
 |
Viridian Therapeutics
VRDN
|
-363 M | $ 23.17 | 1.09 % | $ 2.36 B | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-31.5 M | - | 7.23 % | $ 2.72 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
4.17 B | $ 528.9 | 0.22 % | $ 135 B | USA |
 |
Verastem
VSTM
|
-170 M | $ 8.08 | 0.55 % | $ 560 M | USA |
 |
vTv Therapeutics
VTVT
|
-32.8 M | $ 32.79 | 0.03 % | $ 130 M | USA |
 |
Voyager Therapeutics
VYGR
|
-132 M | $ 3.4 | 3.85 % | $ 200 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-215 M | $ 4.91 | 1.03 % | $ 828 M | Singapore |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-126 M | $ 13.16 | 0.15 % | $ 112 M | USA |
 |
Xenetic Biosciences
XBIO
|
-2.83 M | $ 4.28 | 0.86 % | $ 7.28 M | USA |
|
XBiotech
XBIT
|
-55.7 M | $ 2.18 | 0.23 % | $ 66.5 M | USA |
 |
Exicure
XCUR
|
-4.23 M | $ 1.41 | 12.8 % | $ 8.88 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-373 M | $ 59.55 | 0.18 % | $ 4.72 B |  Canada |
 |
Xeris Pharmaceuticals
XERS
|
24.9 M | $ 8.48 | 0.12 % | $ 1.36 B | USA |